Since the S1-RBD has been considered an immunodominant region and the main target of neutralizing antibodies
Since the S1-RBD has been considered an immunodominant region and the main target of neutralizing antibodies. group, which needed to be Carmofur investigated in the future. Keywords: COVID-19, vaccine, binding antibodies, neutralizing antibodies, anti-ACE2 antibodies Intro COVID-19 pandemic occurred at the end of 2019 and offers caused 624 million infections and 6. 5 million deaths as of 25 October 2022, according to the statistics of World Health Organization (WHO) (1). In addition to the serious health problems, the COVID-19 pandemic offers caused a negative impact on the global economy (2). Scientists worldwide were dedicated to investigating the SARS-CoV-2-related study, especially Rabbit Polyclonal to BRP44 in vaccines and antiviral drug developments to combat coronavirus. To date, you will find eleven COVID-19 vaccines based on different platforms that have been granted emergency use listing (EUL) from the World Health Corporation (WHO) (https://covid19.trackvaccines.org/agency/who also/). The platforms of these granted vaccines include inactivated disease (Covaxin from Bharat Biotech, Covilo from Sinopharm (Beijing), and CoronaVac from Sinovac), non-replicating viral vector (Convidcia from CanSino, Ad26.COV2.S from Janssen, Vaxzevria (AZD1222, ChAdOx1 nCoV-19) from Oxford/AstraZeneca, and Covishield (Oxford/AstraZeneca formulation) from Serum Institute of India), RNA (Spikevax (mRNA-1273) from Moderna and Comirnaty (BNT162-b2) from Pfizer/BioNTech), and protein subunit (Nuvaxovid (NVX-CoV2373) from Novavax and COVOVAX (Novavax formulation) from Serum Institute of India) (3, 4). The strategy of all these vaccine platforms except inactivated disease vaccines is based on the SARS-CoV-2 spike protein. Among these vaccines, Pfizer/BioNTech was the 1st COVID-19 vaccine that has been Carmofur authorized by the U.S. Food and Drug Administration (FDA) in 2021. Subsequently, Moderna, Johnson & Johnson, and Novavax have also been authorized by the FDA in Carmofur 2022 (5, 6). SARS-CoV-2 spike protein is definitely a ~180 kDa glycoprotein that can form a trimeric structure that protrudes from the surface of the viral particle and play a key role in sponsor cell access (7C9). The total length of the SARS-CoV-2 spike protein contains 1273 amino acids (a.a) consisting of a signal peptide (a.a. 1C13 residues), S1 subunit (a.a. 14-685), and S2 subunit (a.a. 686-1273). The S1 subunit consists of a N-terminal website (a.a. 14C305), a receptor-binding domain (S1-RBD, a.a. 319-541), and a receptor-binding motif (RBM, a.a. 437C508). The S2 subunit includes the fusion peptide (a.a. 788C806), heptapeptide repeat sequence 1 (HR1, a.a. 912C984), heptapeptide repeat sequence 2 (HR2, a.a. 1163C1213), transmembrane domain (a.a. 1213C1237), and cytoplasm domain (a.a. 1237C1273) (10). The RBM is definitely a portion of the S1-RBD that makes direct contact with the human being cell surface receptor angiotensin-converting enzyme 2 (ACE2), whereas the S2 subunit mediates subsequent membrane fusion with the sponsor cell membrane by forming a six-helical package the two HR website (7, 11). Within the S1 and S2 subunits, the S1-RBD has been regarded as an immunodominant region and the main target of neutralizing antibodies (12C14). In Taiwan, four COVID-19 vaccines have been granted emergency use authorization (EUA) by Taiwan Food and Drug Administration (TFDA), including AZD1222 (Vaxzevria, Oxford/AstraZeneca), mRNA-1273 (Spikevax, Moderna), BNT162-b2 (Comirnaty, Pfizer/BioNTech), and MVC-COV1901 (Taiwan-based Medigen Vaccine Biologics Corporation) at the study time. With related strategies to NVX-CoV2373 (Novavax), MVC-COV1901 is definitely a protein subunit vaccine adjuvanted with Carmofur CpG 1018 and aluminium hydroxide. To stabilize the prefusion form spike protein for conserving neutralizing epitopes, a GSAS alternative in the S1/S2 furin cleavage sites to confer protease resistance and two proline substitutions at residues 986 and 987 (K986P, V987P) in the sequence of the wild-type spike from your Wuhan strain were integrated (15). Additionally, a trimerization website (IZN4) is added to the C-terminus for improving the conformational homogeneity (16). According to the statistical data from your TFDA site (https://www.cdc.gov.tw/En/File/Get/BlkBAw7kMxwGxCDsPEvtg), a total of 63.17 million doses have been given in Taiwan (mRNA-1273: 23.89 million doses, BNT162-b2: 19.3 million doses, AZD1222: 15.3 million doses, MVC-COV1901: 3.06 million doses) as of October 24th, 2022. Vaccination reduces not only COVID-19 transmission, but also severe illness and deaths from COVID-19 illness (17). However, vaccines could not provide full safety from COVID-19 illness, especially when SARS-CoV-2 has an extremely high mutation.